These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

182 related items for PubMed ID: 22633624

  • 1. Phase II study of vinorelbine and continuous low doses cyclophosphamide in children and young adults with a relapsed or refractory malignant solid tumour: good tolerance profile and efficacy in rhabdomyosarcoma--a report from the Société Française des Cancers et leucémies de l'Enfant et de l'adolescent (SFCE).
    Minard-Colin V, Ichante JL, Nguyen L, Paci A, Orbach D, Bergeron C, Defachelles AS, André N, Corradini N, Schmitt C, Tabone MD, Blouin P, Sirvent N, Goma G, Geoerger B, Oberlin O.
    Eur J Cancer; 2012 Oct; 48(15):2409-16. PubMed ID: 22633624
    [Abstract] [Full Text] [Related]

  • 2. Vinorelbine and low-dose cyclophosphamide in the treatment of pediatric sarcomas: pilot study for the upcoming European Rhabdomyosarcoma Protocol.
    Casanova M, Ferrari A, Bisogno G, Merks JH, De Salvo GL, Meazza C, Tettoni K, Provenzi M, Mazzarino I, Carli M.
    Cancer; 2004 Oct 01; 101(7):1664-71. PubMed ID: 15378498
    [Abstract] [Full Text] [Related]

  • 3. Phase II trial of topotecan administered as 72-hour continuous infusion in children with refractory solid tumors: a collaborative Pediatric Branch, National Cancer Institute, and Children's Cancer Group Study.
    Blaney SM, Needle MN, Gillespie A, Sato JK, Reaman GH, Berg SL, Adamson PC, Krailo MD, Bleyer WA, Poplack DG, Balis FM.
    Clin Cancer Res; 1998 Feb 01; 4(2):357-60. PubMed ID: 9516923
    [Abstract] [Full Text] [Related]

  • 4. Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study.
    Saylors RL, Stine KC, Sullivan J, Kepner JL, Wall DA, Bernstein ML, Harris MB, Hayashi R, Vietti TJ, Pediatric Oncology Group.
    J Clin Oncol; 2001 Aug 01; 19(15):3463-9. PubMed ID: 11481351
    [Abstract] [Full Text] [Related]

  • 5. Phase II evaluation of intravenous vinorelbine (Navelbine) in recurrent or refractory pediatric malignancies: a Children's Oncology Group study.
    Kuttesch JF, Krailo MD, Madden T, Johansen M, Bleyer A, Children's Oncology Group.
    Pediatr Blood Cancer; 2009 Oct 01; 53(4):590-3. PubMed ID: 19533657
    [Abstract] [Full Text] [Related]

  • 6. Ifosfamide, carboplatin, and etoposide (ICE) reinduction chemotherapy in a large cohort of children and adolescents with recurrent/refractory sarcoma: the Children's Cancer Group (CCG) experience.
    Van Winkle P, Angiolillo A, Krailo M, Cheung YK, Anderson B, Davenport V, Reaman G, Cairo MS.
    Pediatr Blood Cancer; 2005 Apr 01; 44(4):338-47. PubMed ID: 15503297
    [Abstract] [Full Text] [Related]

  • 7. Impact of high-dose busulfan plus melphalan as consolidation in metastatic Ewing tumors: a study by the Société Française des Cancers de l'Enfant.
    Oberlin O, Rey A, Desfachelles AS, Philip T, Plantaz D, Schmitt C, Plouvier E, Lejars O, Rubie H, Terrier P, Michon J, Société Française des Cancers de l'Enfant.
    J Clin Oncol; 2006 Aug 20; 24(24):3997-4002. PubMed ID: 16921053
    [Abstract] [Full Text] [Related]

  • 8. Phase I evaluation of oral and intravenous vinorelbine in pediatric cancer patients: a report from the Children's Oncology Group.
    Johansen M, Kuttesch J, Bleyer WA, Krailo M, Ames M, Madden T.
    Clin Cancer Res; 2006 Jan 15; 12(2):516-22. PubMed ID: 16428494
    [Abstract] [Full Text] [Related]

  • 9. Efficacy of topotecan and cyclophosphamide given in a phase II window trial in children with newly diagnosed metastatic rhabdomyosarcoma: a Children's Oncology Group study.
    Walterhouse DO, Lyden ER, Breitfeld PP, Qualman SJ, Wharam MD, Meyer WH.
    J Clin Oncol; 2004 Apr 15; 22(8):1398-403. PubMed ID: 15007087
    [Abstract] [Full Text] [Related]

  • 10. Phase II trial of cisplatin and etoposide in children with advanced soft tissue sarcoma: a report from the Italian Cooperative Rhabdomyosarcoma Group.
    Carli M, Perilongo G, di Montezemolo LC, De Bernardi B, Ceci A, Paolucci G, Pianca C, Calculli G, Di Tullio MT, Grotto P.
    Cancer Treat Rep; 1987 May 15; 71(5):525-7. PubMed ID: 3567976
    [Abstract] [Full Text] [Related]

  • 11. A phase 2 trial of trabectedin in children with recurrent rhabdomyosarcoma, Ewing sarcoma and non-rhabdomyosarcoma soft tissue sarcomas: a report from the Children's Oncology Group.
    Baruchel S, Pappo A, Krailo M, Baker KS, Wu B, Villaluna D, Lee-Scott M, Adamson PC, Blaney SM.
    Eur J Cancer; 2012 Mar 15; 48(4):579-85. PubMed ID: 22088484
    [Abstract] [Full Text] [Related]

  • 12. Vinorelbine and cisplatin (CIVIC regimen) for the treatment of metastatic breast carcinoma after failure of anthracycline- and/or paclitaxel-containing regimens.
    Ray-Coquard I, Biron P, Bachelot T, Guastalla JP, Catimel G, Merrouche Y, Droz JP, Chauvin F, Blay JY.
    Cancer; 1998 Jan 01; 82(1):134-40. PubMed ID: 9428489
    [Abstract] [Full Text] [Related]

  • 13. Topotecan and cyclophosphamide in patients with refractory or relapsed Ewing tumors.
    Hunold A, Weddeling N, Paulussen M, Ranft A, Liebscher C, Jürgens H.
    Pediatr Blood Cancer; 2006 Nov 01; 47(6):795-800. PubMed ID: 16411206
    [Abstract] [Full Text] [Related]

  • 14. Comparison of dose intensity of vincristine, d-actinomycin, and cyclophosphamide chemotherapy for child and adult rhabdomyosarcoma: a retrospective analysis.
    Kojima Y, Hashimoto K, Ando M, Yonemori K, Yamamoto H, Kodaira M, Yunokawa M, Shimizu C, Tamura K, Hosono A, Makimoto A, Fujiwara Y.
    Cancer Chemother Pharmacol; 2012 Sep 01; 70(3):391-7. PubMed ID: 22806306
    [Abstract] [Full Text] [Related]

  • 15. Phase II results from a phase I/II study to assess the safety and efficacy of weekly nab-paclitaxel in paediatric patients with recurrent or refractory solid tumours: A collaboration with the European Innovative Therapies for Children with Cancer Network.
    Amoroso L, Castel V, Bisogno G, Casanova M, Marquez-Vega C, Chisholm JC, Doz F, Moreno L, Ruggiero A, Gerber NU, Fagioli F, Hingorani P, Melcón SG, Slepetis R, Chen N, le Bruchec Y, Simcock M, Vassal G.
    Eur J Cancer; 2020 Aug 01; 135():89-97. PubMed ID: 32554315
    [Abstract] [Full Text] [Related]

  • 16. Relapse after localized rhabdomyosarcoma: Evaluation of the efficacy of second-line chemotherapy.
    Winter S, Fasola S, Brisse H, Mosseri V, Orbach D.
    Pediatr Blood Cancer; 2015 Nov 01; 62(11):1935-41. PubMed ID: 26150380
    [Abstract] [Full Text] [Related]

  • 17. Retrospective Analysis of Outcomes of Patients with Relapsed, Refractory and Metastatic Sarcomas who have received Metronomic Chemotherapy.
    Devadas SK, Banavali S.
    Gulf J Oncolog; 2019 May 01; 1(30):22-28. PubMed ID: 31242978
    [Abstract] [Full Text] [Related]

  • 18. Concomitant administration of vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide for high-risk sarcomas: the St. Jude Children's Research Hospital experience.
    Navid F, Santana VM, Billups CA, Merchant TE, Furman WL, Spunt SL, Cain AM, Rao BN, Hale GA, Pappo AS.
    Cancer; 2006 Apr 15; 106(8):1846-56. PubMed ID: 16541446
    [Abstract] [Full Text] [Related]

  • 19. Phase I expansion cohort to evaluate the combination of bevacizumab, sorafenib and low-dose cyclophosphamide in children and young adults with refractory or recurrent solid tumours.
    Federico SM, Caldwell KJ, McCarville MB, Daryani VM, Stewart CF, Mao S, Wu J, Davidoff AM, Santana VM, Furman WL, Pappo AS, Navid F.
    Eur J Cancer; 2020 Jun 15; 132():35-42. PubMed ID: 32325418
    [Abstract] [Full Text] [Related]

  • 20. Phase II trial of a combination of vinorelbine, cyclophosphamide and 5-fluorouracil in the treatment of advanced breast cancer.
    Ardavanis A, Extra JM, Espié M, Cuvier C, Marty M.
    In Vivo; 1998 Jun 15; 12(5):559-62. PubMed ID: 9827368
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.